Clinical Characteristics and Burden of Illness in Pediatric Patients with Narcolepsy by Plazzi, Giuseppe et al.
Pediatric Neurology 85 (2018) 2132
Contents lists available at ScienceDirect
Pediatric Neurology
journal homepage: www.elsevier .com/locate/pnuTopical ReviewClinical Characteristics and Burden of Illness in Pediatric Patients
with Narcolepsy
Giuseppe Plazzi, MD, PhD a,b,*, Heather M. Clawges, MD c, Judith A. Owens, MD, MPH d
a Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy
b IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
c Department of Pediatrics, Sleep Medicine, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown,
West Virginia
d Division of Neurology, Boston Children's Hospital, Harvard Medical School, Waltham, MassachusettsARTICLE INFO
Article history:
Received 20 December 2017
Accepted 19 June 2018*Corresponding author.
E-mail address: giuseppe.plazzi@unibo.it
https://doi.org/10.1016/j.pediatrneurol.2018.06.008
0887-8994/© 2018 The Authors. Published by Elsevi
(http://creativecommons.org/licenses/by-nc-nd/4.0/)ABSTRACT
BACKGROUND: Narcolepsy is a chronic and lifelong neurologic disorder with onset commonly
occurring in childhood or adolescence, and affecting approximately 0.025% to 0.05% of the gen-
eral population. The primary symptom is excessive daytime sleepiness, which is accompanied
by cataplexy in 70% of patients. Other common symptoms include sleep paralysis, hallucinations
upon falling asleep or waking, and disrupted nocturnal sleep. Narcolepsy is associated with a
considerable burden of illness (BOI), which has been well characterized in adults, and is exacer-
bated by delays in symptom recognition, diagnosis, and intervention. METHODS: This review
describes the specific characteristics and BOI of pediatric narcolepsy, using a wide range of pub-
lished research data. RESULTS: Pediatric narcolepsy presents distinct challenges in diagnosis and
management. Narcolepsy symptoms often initially manifest differently in children and adoles-
cents versus adults, which may pose diagnostic dilemmas. Children often respond to sleepiness
with irritability, hyperactivity, and poor attention, which may be misinterpreted as misbehavior
or neurocognitive sequelae of other conditions. Pediatric cataplexy symptoms may include sub-
tle and unusual facial expressions or choreic-like movements, which are not observed in adults.
Insufficient sleep and circadian rhythm disorders presenting with excessive daytime sleepiness
are common in adolescents, potentially confounding narcolepsy diagnosis. Pediatric narcolepsy
is also associated with comorbidities including rapid weight gain, precocious puberty, and atten-
tion deficit hyperactivity disorder, and increased risk for deficits in social functioning, depres-
sion, and anxiety. School performance is also typically impaired, requiring special education
services. CONCLUSIONS: Thus, the discrete BOI of pediatric narcolepsy underscores the need for
prompt and accurate diagnosis, and appropriate treatment of this disorder.







psychosocial problemser Inc. This is an open access article under the CC BY-NC-ND license.Introduction
Narcolepsy is a chronic and lifelong neurological disor-
der characterized by excessive daytime sleepiness (EDS)
and cataplexy, with two distinct subtypes, narcolepsy
type 1 (NT1) and narcolepsy type 2 (NT2).1,2 Symptom
onset of NT1 and NT2 typically occurs in the second orthird decade of life with 50% to 65% of patients present-
ing before the age of 20 years.3-8 Narcolepsy is a rare
form of chronic hypersomnolence, with an estimated
prevalence of 0.025% to 0.05% of the general population
in the United States (US) and Western Europe.2,4,9-11
Globally reported narcolepsy prevalence rates have
ranged from as high as 0.16% in Japan and 0.28% in China
FIGURE 1. Health-related quality of life (Medical Outcomes Study Short Form-12 and Short Form-36) for adult patients (mean age »47 years)
diagnosed with narcolepsy versus control subjects matched for age, sex, race, and multiple health and socioeconomic factors. Analysis of data
from the 2011, 2012, and 2013 United States National Health and Wellness Survey. Error bars represent standard errors. All comparisons for
each outcome were significant at the P < 0.001 level. Adapted from Flores et al.25
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Epidemiologic data suggest males may have higher prev-
alence of narcolepsy than females (1.6 to 1.8 versus 1);
however, this difference could be related to referral bias.1
Pediatric narcolepsy presents a distinct set of challenges
with regard to its recognition and diagnosis, its impact on
patients and their parents or caregivers, and its effect on
other involved individuals.12-15 In addition, multiple studies
have found that the diagnosis of narcolepsy is delayed by a
mean of approximately 15 years after onset of symptoms,
often likely due to poor recognition and attribution of symp-
toms by health care providers and leading to a wide variety
of misdiagnoses, which further contributes to the burden of
illness (BOI) of narcolepsy.8,16-18 In addition, a cross-sec-
tional survey of 1699 individuals (92% greater than 18 years
old) in the US with a self-reported diagnosis of narcolepsy
found that pediatric onset of symptoms was the strongest
predictor of delayed diagnosis of more than year (P <
0.0005).19 Multiple studies have reported that narcolepsy
imposes a substantial BOI on adults in terms of reduced
quality of life (QOL) and/or health-related QOL and socioeco-
nomic costs (Fig 1).20-25 Although fewer data are available
on BOI in children with narcolepsy, recently published stud-
ies have begun to address this neglected area.26-32
Following a basic review of the clinical characteristics
of narcolepsy, we will profile pediatric narcolepsy with a
specific focus on BOI in children and adolescents with
this disorder. With regard to methodology, it should be
noted that any review of the clinical characteristics and
BOI of a chronic pediatric disease is limited by difficulties
in obtaining patient-reported data, and the absence of
certain highly quantifiable adult BOI parameters such as
income, employment, career, marriage, and family. How-
ever, the study of pediatric BOI raises a wide range of
highly impactful developmental issues and parameters,
such as schooling, socialization, and physical, psychiatric,and endocrinal growth and health, which may greatly
influence later stages of life. To adjust for these factors,
we have used a wide range of published research data,
including observational reports, controlled studies, case
studies, and reviews available through the National
Library of Medicine/PubMed database.
Narcolepsy symptoms and subtypes
EDS in narcolepsy in adults and children is character-
ized by frequent and extreme drowsiness, most often
occurring during passive conditions (e.g., reading, sitting
quietly in a classroom or following lunch, or riding in a
motor vehicle). The sleepiness is very difficult to resist
and can result in involuntary sleep bouts that may also be
very brief (“micro-sleeps”) or more prolonged (unplanned
or inadvertent “naps”). Increased nocturnal sleep duration
and planned naps can also occur. While EDS is shared in
both NT1 and NT2,33 cataplexy occurs only in NT1, also
called narcolepsy with cataplexy. NT1 accounts for
approximately 70% of all narcolepsy cases.11,34 Conversely,
NT2, also called narcolepsy without cataplexy, is clinically
distinguished from NT1 by the absence of cataplexy symp-
toms, as defined in the third edition of the International
Classification of Sleep Disorders, (ICDS-3; Table 1).2 It has
been estimated that 10% of patients initially diagnosed
with NT2 may be reclassified to NT1 with development of
cataplexy symptoms, which typically appear within
five years but may be delayed up to 20 years, and can be
foretold by evidence of significant hypocretin defi-
ciency.35-37
Considered pathognomonic for NT1, cataplexy is char-
acterized by abrupt and brief (typically less than two
minutes in duration) episodes of loss of voluntary muscle
tone, usually bilateral and ranging from a subtle sensa-
tion of weakness involving the knees or craniocervical
TABLE 1. Diagnostic Criteria for Narcolepsy Type 1 and Type 2: International
Classification of Sleep Disorders2
Narcolepsy Type 1
Alternate names: Hypocretin deficiency syndrome, narcolepsy-cataplexy,
narcolepsy with cataplexy
Diagnostic criteria
 Criteria A and B must be met.
A. The patient has daily periods of irrepressible need to sleep or day-
time lapses into sleep occurring for at least 3 months.
B. The presence of one or both of the following:
(1) Cataplexy and a mean sleep latency of 8 minutes, and two or
more sleep onset rapid eye movement periods (SOREMPs) on a Multiple
Sleep Latency Test (MSLT) performed per standard techniques. A SOREMP
(within 15 minutes of sleep onset) on the preceding nocturnal polysom-
nogram may replace one of the SOREMPs on the MSLT.
(2) Hypocretin-1 concentration in the cerebrospinal fluid (CSF),
measured by immunoreactivity is either 110 pg/mL or less than one
third of mean values obtained in normal subjects with the same standard-
ized assay.15
Narcolepsy Type 2
Alternate names: Narcolepsy without cataplexy
Diagnostic criteria
 Criteria A through E must be met.
A. The patient has daily periods of irrepressible need to sleep or day-
time lapses into sleep occurring for at least 3 months.
B. A mean sleep latency of 8 minutes and two or more SOREMPs are
found on the MSLT performed per standard techniques. A SOREMP (within
15 minutes of sleep onset) on the preceding nocturnal polysomnogram
may replace one of the SOREMPs on the MSLT.
C. Cataplexy is absent.
D. Either CSF hypocretin-1 concentration has not been measured or
CSF hypocretin-1 concentration measured by immunoreactivity is either
greater than 110 pg/mL or greater than one third of mean values obtained
in normal subjects with the same standardized assay.
E. The hypersomnolence and/or MSLT findings are not better
explained by other causes such as insufficient sleep, obstructive sleep
apnea, delayed sleep phase disorder, or the effect of medication or sub-
stances or their withdrawal.
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jaw), to complete body paralysis leading to falls.1,34,38
Consciousness is retained during episodes and positive
motor phenomena including muscle twitching or small
jerks of the face or limbs may also be observed.1,34
Strong emotions typically trigger cataplexy episodes,
most commonly laughter and surprise. Fright, anger, and
startle are other potential triggers.34,39-41 Other common
symptoms of both NT1 and NT2 include sleep paralysis
(inability to voluntarily initiate muscle movement except
for extraocular muscles) and visual, auditory, tactile, and/
or multisensory (e.g., sensed presence of an “intruder”)
hallucinations, both of which may be hypnagogic (while
falling asleep) or more typically hypnopompic (upon
waking) in terms of timing. These phenomena are
thought to represent the “intrusion” of rapid eye move-
ment (REM) sleep-related phenomena (muscle atonia and
dream mentation) into the waking state.42 NT1 is also
frequently associated with disrupted nocturnal sleep,
with sleep fragmentation possibly characterized by awak-
enings, increased motor activity, and dream enactment,
resulting in a “pentad” of clinical features.1,2
Pathophysiology and risk factors
Although the pathophysiology of narcolepsy is not
completely understood, NT1 is linked to the complete ornear-complete loss of hypocretin-producing neurons of
the dorsolateral hypothalamus, as measured by hypocre-
tin-1 in cerebrospinal fluid (CSF)43 and documented in
postmortem brains.44 Hypocretin (also termed orexin) is
a neuropeptide neurotransmitter that is critical to main-
taining wakefulness and arousal as well as other func-
tions such as appetite control and energy metabolism,
regulation of the neuroendocrine, cardiovascular and gas-
trointestinal systems, and pain modulation.45 The natural
history of NT2 and its correlation with hypocretin
(orexin) loss is less clear, although approximately 10% to
30% of patients with NT2 may have reduced levels of CSF
hypocretin-1,36 and a significant reduction of hypocretin
neurons has been documented in two postmortem
examinations.46 A study in 171 patients with NT2 found
that 24% had low CSF hypocretin (orexin) levels versus
healthy control subjects.35 Moreover, almost half of the
patients in this study with low CSF hypocretin-1 levels
(48%) went on to develop cataplexy in their lifetime, after
a delay of four to 26 years, compared with 2% of those
with normal hypocretin levels.35
Documented risk factors for narcolepsy include both
genetic and environmental factors, with a likely combina-
tion of both. Considerable basic science evidence sup-
ports the hypothesis that the loss of hypocretin (orexin)
neurons in narcolepsy has an autoimmune etiology
linked to both an underlying genetic predisposition and
environmental triggers in susceptible individuals, precipi-
tating cell loss.1,9,47 Isolated narcolepsy symptoms have
been reported in up to 11% of individuals with first
degree relatives who have and/or had the condition.48
Specific genetic risks include a strong association with
human leukocyte antigen DQB1*06:02, and reported cor-
relations with T-cell receptor polymorphisms and anti-
bodies to the protein Tribbles homolog 2.47,49-53
Suspected environmental risk factors include H1N1 infec-
tion or specific H1N1 vaccination (namely Pandemrix)
and seasonal upper airway infections, including Strepto-
coccal infection, although none of these correlations are
conclusive.6,54-58 “Secondary” NT1 or NT2 may also occur
in association with other neurological conditions, injury,
or genetic diseases, including traumatic brain injury
involving damage to the hypothalamus, Guillain-Barre
syndrome, limbic encephalitis, multiple sclerosis, congen-
ital brain malformations, Niemann-Pick disease type C,
the DNMT1 gene, and other inherited neurodegenerative
conditions with broad multisystem involvement.1,54
Epidemiology, presentation, and symptomatology in pediatric
narcolepsy
Prevalence, age of onset, gender distribution
Although multiple studies have reported on the overall
prevalence of narcolepsy, the prevalence specifically in
children is less well studied.55 A large European study
(approximately 280 person years of observation time)
estimated the prevalence of narcolepsy to be 0.13 per
100,000 children aged less than five years, and 0.83 per
100,000 children aged five to 19 years.55,56 Studies in
pediatric cohorts (aged less than 18 years) diagnosed
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onset of symptoms of approximately nine to
ten years.6,55,57-61 Occurrence in children less than five or
six years old is rare,62 with a prevalence of approxi-
mately 5% in pediatric narcolepsy cohort studies that
have reported these data.57,63 However, a study in 271
Chinese children with NT1 reported a mean age of onset
of eight years, with prepubertal onset in 76% and onset
at five years or younger in 15%.64 As in adults,1 gender
does not seem to be an important factor in pediatric nar-
colepsy prevalence, although a slight preponderance of
boys over girls has been reported.57,59-61,65
Clinical symptoms and presentation
The major narcolepsy symptoms in children are simi-
lar to those in adults, as described above.66 However, the
initial clinical manifestations of these symptoms may dif-
fer significantly between children and adults.1,67 All
patients with narcolepsy manifest EDS and this symptom
is usually the first to appear in both children and adults;
however, children may display distinct, developmentally
related responses to sleepiness.59,62,67 Children with nar-
colepsy have been observed to exhibit hyperactivity, irri-
tability and emotional dysregulation, aggression,
distractibility, and impulsiveness or restlessness both
during the day and at bedtime. These behaviors may
reflect the child's external response to an internal feeling
of sleepiness and/or an attempt to resist it by engaging
in self-stimulatory behavior, possibly leading to a clinical
presentation that overlaps with attention deficit hyperac-
tivity disorder (ADHD).39,55,65,67 In preschool children,
daytime napping behavior suggestive of EDS may overlap
with normal, physiologic napping patterns for this age
group,62 but resumption of napping in an older child
may be an initial presentation of EDS. Naps may also be
longer than those in adults, lasting up to two to
three hours in preschool and school-age children, and are
more often nonrestorative.12,62 Sleep “drunkenness” and
extreme difficulty in arousing children in the morning,
accompanied by aggressive behavior or tantrums, are
additional behaviors sometimes associated with EDS in
pediatric narcolepsy.12,39,57,67
Cataplexy in children usually presents either concomi-
tant with EDS or within one to three years of EDS and
other initial symptoms.16,18,39,57,67 Cataplexy in the pedi-
atric population can have different clinical features, cre-
ating diagnostic challenges.18 One study that compared
narcolepsy symptomatology in 31 children (aged 10 to
19) versus 117 adults (aged 20) found that almost half
of the children (48.4%) did not have cataplexy symptoms
and thus were diagnosed with NT2, compared with only
20.5% of adults diagnosed as NT2 (P < 0.01).66 However,
the mean age difference from symptom onset to diagno-
sis in this study was only 1.8 (§1.7) years for children
versus 26.5 (§16.6) years for adults (P < 0.001). There-
fore, cataplexy symptoms may still develop over time,
especially among at-risk children (e.g., those with low
CSF hypocretin-1 levels).35,66 Studies in other cohorts
have found that EDS and narcolepsy present simulta-
neously in childhood narcolepsy, and cataplexysymptoms often initially manifest differently in children
compared with adults.18,34,39,61 Features common in chil-
dren and atypical in adults include hypotonic attacks
occurring often without identifiable triggers (spontane-
ously), with prolonged duration, and prominent, facial
and/or jaw and eyelid weakness (ptosis) with spontane-
ous tongue protrusion (“cataplectic facies”)39,68 often
accompanied by neck extension; slurred speech; a com-
plex array of movements, including facial grimacing; and
automatic behaviors such as self-scratching and touch-
ing.18,39,61 In particular, cataplectic facies are distinctive
to the pediatric population. “Puppet” or choreic-like
whole-body movements with hypotonia have also been
observed.18 These movements are also exacerbated by
emotions, identifying them as variants of cataplexy.18
These symptoms typically progress with the course of
the disease to the eventual clinical presentation of classi-
cal cataplexy occurring most commonly in response to
emotional triggers.61
Most children also develop at least one of the associ-
ated symptoms other than EDS and cataplexy, with vari-
able reported prevalence,55 although the “classic” pentad
of symptoms (EDS, cataplexy, sleep paralysis, hypnogogic
and/or hypnopompic hallucinations, and nocturnal sleep
disturbances) infrequently develop simultaneously at the
onset of narcolepsy symptoms in children. Rapid weight
gain and precocious puberty often accompany symptoms
of pediatric narcolepsy in children, and will be discussed
in more detail below.60 Other clinical characteristics
include increased periodic limb movements in chil-
dren,59,69 as in adults with narcolepsy,3 and REM sleep
behavior disorder, which in pediatric narcolepsy usually
only occurs in NT1 children with the most severe
symptoms.69,70
Diagnostic criteria and challenges
In children as in adults, narcolepsy is formally diag-
nosed and designated as either NT1 or NT2, based on
clinical evaluation and physical examination, symptoms,
and the results of objective sleep testing and/or CSF
hypocretin-1 assay, according to the criteria established
by the ICDS-3 (Table 1).2
Although the ICSD-3 generally recommends the same
criteria for diagnosis in adults and children, it has also
issued several caveats with regard to developmental
issues in the pediatric population, including differences
in symptomatology from adult presentation, as described
above (see Epidemiology, Presentation, and Symptom-
atology in Pediatric Narcolepsy: Clinical Symptoms and
Presentation), and limited ability of especially younger
children to articulate some symptoms, particularly sleep
paralysis and hallucinations.2 Both clinical characteristics
of narcolepsy and sleep testing results may also differ
between prepubertal patients and adolescents (Table 2).
The primary sleep diagnostic tools used to supplement
the clinical evaluation and help confirm the diagnosis
include a nocturnal polysomnogram/polysomnography
(PSG) followed by a Multiple Sleep Latency Test (MSLT).
The latter is a series of five 20-minute nap opportunities
separated by two-hour intervals that is conducted on the
TABLE 2. Characteristics of Patients With Pediatric Prepubertal Versus Adolescent Onset of Narcolepsy*12,18,60
Symptom/Characteristic Prepubertal Onset Adolescent Onset
Excessive sleepiness Sleep “attacks” more constant and of longer duration Less frequent and shorter naps
MSLT results Longer mean sleep latency, MSLT more commonly negative Shorter mean sleep latency, MSLT more commonly false-positive
due to adolescent sleep phase delay, poor sleep hygiene, and
chronic sleep deprivation
Cataplexy More severe (may indicate more severe course of disease) Less severe
Sleep paralysis Less prevalent and severe More prevalent and severe
Negative motor phenomenay More common Less common
* All relative terms (e.g., more and less) refer to the onset age group versus the other onset age group.
y Partial or generalized hypotonia, ptosis, and tongue protrusion.
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meets criteria for narcolepsy in terms of both sleep pro-
pensity (mean sleep onset latency less than 8 minutes)
and rapid initiation of REM sleep (the presence of sleep
onset rapid eye movement periods or SOREMPs on two
or more of the naps), which is considered the most
pathognomonic objective feature of NT2.2 A REM period
occurring within the first 15 minutes of the nocturnal
PSG may be counted as one of the SOREMPs. Interpreta-
tion of the PSG and MSLT in the pediatric population,
however, is not necessarily straightforward and may be
complicated by multiple factors that can produce either
false-negative or false-positive results. These include the
lack of established normative values for the MSLT in pre-
pubertal children, the fact that severely sleep-deprived
adolescents without narcolepsy can have a very short
mean sleep onset latency and even SOREMPs, and diffi-
culties children may have understanding or complying
with testing instructions.12,71
Other factors may influence the MSLT results such as
comorbid sleep disorders, including obstructive sleep
apnea and periodic leg movement disorder, which may
increase sleepiness; concomitant use of (or withdrawal
from) REM suppressing medications such as many antide-
pressants; and current substance use. In some cases of
“emerging” narcolepsy in children, the MSLT may need to
be repeated several times before a clear diagnosis can be
made. A CSF hypocretin-1 concentration of 110 pg/mL
or less than one third of mean values in normal subjects
is the biological marker of NT1; however, this test is cur-
rently not widely used due to limited availability and the
need to conduct a lumbar puncture.34,72 Because cata-
plexy is absent in NT2 and thus SOREMPs are not
required for the diagnosis, this form of narcolepsy is par-
ticularly difficult to diagnose36 as EDS alone may indicate
other conditions such as sleep deprivation or idiopathic
hypersomnia. Indeed, studies indicate MSLT is less reli-
able for diagnosis of NT2 than for NT1, and often requires
repeat testing when NT2 is suspected.73-75 A diagnostic
algorithm for NT2 diagnosis (nonspecific to age) has been
proposed (Fig 2).36
Interpretation of clinical evaluation and symptomatol-
ogy is also particularly difficult in pediatric narcolepsy,
with high potential for misinterpretation.65,76,77 For
example, the distinction between “sleepiness” and
“fatigue,” as in adults, is not always clear. Thus, EDS in
children, especially when combined with symptoms of
attentional, behavioral, and emotional dysregulation, maybe misinterpreted as “laziness,” depression, chronic
fatigue syndrome, or endocrine problems such as hypo-
thyroidism. Cataplexy episodes can be confused with nor-
mal falls, clumsiness, seizures, or neuromuscular
disorders, and hypnagogic hallucinations are sometimes
misinterpreted as nightmares or “night terrors” or even
as evidence of psychosis in children and adoles-
cents.12,18,65,76-79 The behavioral symptoms commonly
associated with EDS in children with narcolepsy, such as
irritability, emotional lability, poor attentiveness in
school, aggressiveness, insomnia, hallucinations, or social
withdrawal, may be misinterpreted as ADHD, conversion
disorder, oppositional defiant disorder, depression or
schizophrenia.2,26,65,76,80 Indeed, the child's teacher is
frequently one of the first to report problems eventually
leading to narcolepsy diagnosis, including poor attention
span, hyperactivity, distractibility, learning problems and
academic underperformance, especially in comparison to
the child's general cognitive ability (Table 3).65,67 Emerg-
ing study data also suggest that psychiatric and/or neuro-
developmental disorders such as ADHD, oppositional
defiant disorder, and depression may be comorbid with
narcolepsy in some patients,26,31,80,81 as discussed below
(see Burden of Illness (BOI) of Pediatric Narcolepsy:
Correlates and Comorbidities: ADHD and Other Neuro-
logical/Psychiatric Comorbidities).
In adolescents, narcolepsy symptoms such as sleepiness,
mood dysregulation, and inattention may be labeled as
behaviors related to “hormonal changes” in puberty.82
Delayed sleep-wake phase disorder is a common circa-
dian-rhythm disorder in adolescents in which the pre-
ferred nocturnal sleep onset and morning wake times are
both significantly delayed and thus result in significant
EDS when the individual is required to wake for regular
morning activities such as school at a time which conflicts
with their circadian clock; these manifestations may also
mimic narcolepsy.59 Furthermore, the average high school
student obtains far less than the 8.5 to 10 hours of sleep
recommended for optimal functioning and as a result, EDS
is extremely common in this population.83 However, EDS
symptoms associated with insufficient sleep and sleep-
phase delay typically are reduced or even disappear when
the adolescent is able to obtain enough sleep to meet
sleep needs over a period of time (e.g., on school vacations
and during the summer) thus helping to differentiate
these conditions from narcolepsy.59
In addition to PSG and MSLT assessments, prolonged
recording of rest and/or activity behavior by actigraphy is
FIGURE 2. Proposed algorithm for the diagnosis of NT2 and its differential diagnoses. CSF, cerebrospinal fluid; EDS, excessive daytime sleepi-
ness; ESS, Epworth Sleepiness Scale; hcrt-1, hypocretin-1; IH, idiopathic hypersomnia; MSL, mean sleep latency; MSLT, Multiple Sleep Latency
Test; NT1, narcolepsy type 1; NT2, narcolepsy type 2; SOREMP, sleep onset rapid eye movement period. Adapted from Baumann et al.36 aIn
patients with an atypical history or neurological deficits, other causes of narcolepsy-like findings should be considered, and a brain magnetic
resonance imaging should be performed. Children with NT2 should receive a more extensive evaluation for unusual causes of sleepiness (e.g.,
tumors, metabolic disorders, and seizures). bSleep logs or preferably actigraphy over 14 days should be performed before the polysomnogra-
phy (PSG) and MSLT to exclude insufficient sleep syndrome. cDuring the nocturnal PSG, the patient should be permitted their habitual amount
of sleep. dMSLT should be performed according to American Academy of Sleep Medicine guidelines, and medications that might alter sleep
pressure or rapid eye movement sleep should be discontinued well in advance. eAccording to International Classification of Sleep Disorders,
third edition criteria, one SOREMP within 15 minutes of sleep onset on the preceding nocturnal PSG can be included in the total SOREMP
count. fIn patients without cataplexy, CSF hypocretin is recommended to distinguish NT1 from NT2. gA clinical evaluation of frequent hypna-
gogic and/or hypnopompic hallucinations, frequent sleep paralysis, fragmented nocturnal sleep, or positive HLA DQB1*06:02 typing may
increase the likelihood of NT2. hSleep inertia, the need for multiple alarm clocks, and long but unrefreshing daytime naps are more indicative
of idiopathic hypersomnia. iIn patients with normal hypocretin levels, the MSLT should be repeated, preferably after a period of documented
sleep extension.
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circadian phase disorders in children with EDS,2,84 but
also promises to be an objective marker in the diagnosis
of NT1 in adults and in children.84,85 Moreover, since
actigraphy is a noninvasive method that providesTABLE 3. Schooling and Psychosocial Problems in Children with
Narcolepsy27,65,67,76
Poor attention and concentration
Irritability and emotional lability
Memory deficits
Tardiness and forgetfulness
Being disciplined and embarrassed for falling asleep
Stigmatization by school personnel as lazy, “dull,” and unmotivated
Evaluation by school counselors for behavioral problems and consideration
for enrollment in special education classes
False accusations of drug abuse
Aversion to going to school because of conflicts with teachers and peers
Absenteeism, dropping out of school
Difficulty with athletics due to cataplexy or sleepiness
Social isolation and decreased participation in after-school activities
Bullying, feelings of shame and fear of ridiculecircadian measures collected in the subject's natural
environment for long periods, it represents a particularly
valuable approach to assess pediatric patients at baseline
and to monitor the subjective efficacy of and adherence
to therapeutic interventions (pharmacologic and non-
pharmacologic). Regardless of the diagnostic approach,
the failure to screen for EDS and identify potential
causes, and failure to diagnose narcolepsy accurately pro-
longs and exacerbates the associated scholastic, psycho-
social, and psychiatric problems associated with
narcolepsy in children.65,67,76
BOI of pediatric narcolepsy: Correlates and comorbidities
Weight gain and precocious puberty
Studies have documented multiple clinical correlates
and comorbidities of narcolepsy in children that may
have a significant impact on BOI, including elevated body
mass index compared with control subjects.60,80,81,86-88
Rapid weight gain coinciding with the onset of other
G. Plazzi et al. / Pediatric Neurology 85 (2018) 2132 27pediatric narcolepsy symptoms, such as EDS, and subse-
quently resulting in obesity has been among the most
long-standing and consistently observed corre-
lates.6,26,57,60,80,87,89 However, only one study described
the time relation between NT1 onset and weight
increase.88 Reported obesity rates have ranged from
approximately 25% to 75% of children with narco-
lepsy,80,86-89 and body mass index has been shown to be
significantly higher in pediatric narcolepsy patients ver-
sus control subjects.80,86 While weight gain and obesity
have been primarily documented in NT1, they have also
been reported in NT2, although at slightly lower rates.80
Hypothesized causes of obesity in pediatric narcolepsy
include decreased binding of the appetite-suppressing
hormone leptin in the hypothalamus due to reduction of
leptin receptors in hypocretin (orexin) neurons, leading
to hyperphagia, and altered energy homeostasis with a
decreased basal metabolic rate.86,90 Some data suggest
that obese children with narcolepsy may have lower
sleep efficiency, are at higher risk for sleep apnea, and
have higher rates of fatigue and school absenteeism ver-
sus nonobese children with narcolepsy.91
Precocious puberty (early onset compared with devel-
opmental norms in girls and boys) has been correlated
with NT1 in several studies,87,88,92 and in one study
was reported to occur in 17% of children with NT1 versus
1.9% in obese control subjects.87 Patients with precocious
puberty in this study were younger age at onset and/or
diagnosis of NT1, and weight gain or obesity was not
associated with an increased risk of precocious puberty.87
However, another study found that early puberty was
associated with weight gain, although it did not appear
to be an independent association.60
ADHD and other neurological/psychiatric comorbidities
A 2015 study compared scores on an ADHD rating
scale in children younger than 18 years with NT1 (n = 86)
or NT2 (n = 33) versus 67 healthy control subjects.80 In
this study, total scores on the ADHD rating scale were
significantly higher in both NT1 patients (14.2%;
P < 0.001) and NT2 patients (12.2%; P < 0.01) versus con-
trol subjects (6.4%), with no significant difference
between NT1 and NT2.80
Another study of 38 pediatric patients with narco-
lepsy, including 31 post-H1N1 vaccination (PHV) patients
and seven non-PHV patients, reported an overall ADHD
prevalence of 28%, based on ADHD rating scale scores,
which was approximately four times the rate in the gen-
eral population (Sweden).81 This study also reported ele-
vated rates of major depression, anxiety disorder, and
oppositional defiant disorder in PVH patients, compared
with reference rates in the general pediatric popula-
tion.81 The most frequent psychiatric symptom was tem-
per tantrums, present in 94% of PHV patients and 71% of
non-PHV patients. While none of the patients had mental
disability, based on Wechsler intelligence scales, scores
for the Verbal Comprehension Index and the Working
Memory Index were significantly lower in the PHV group
compared with normal reference values.81 The investiga-
tors hypothesized that these psychiatric and cognitivedeficits could be secondary to sleepiness or other aspects
of sleep dysregulation, or to neurological decrements
related to the pathology of narcolepsy and hypocretin
(orexin) loss.81 In addition, a Danish registry study found
that rates of psychiatric disorders were significantly
higher in 243 patients with narcolepsy aged less than
19 years, both before and after their diagnosis, versus
970 matched control subjects (P < 0.0001 for all compar-
isons).93 This study also reported significantly higher
rates of endocrine, nutritional, and metabolic disease
both before and after diagnosis in the narcolepsy patients
versus control subjects (P = 0.001 for both time periods).
BOI: The patient's perspective
While few qualitative studies on the BOI of narcolepsy
for children and adolescents have been published, the
existing data help characterize the impact of narcolepsy
from the patient and caregivers point of view. A study in
40 prepubertal patients aged  seven years who were
given a brief psychiatric interview found that 90% of the
patients wanted to hide their symptoms from peers and
90% were ashamed of their symptoms.65 In addition, 80%
of these patients had feelings of helplessness with their
symptoms; 83% regarded their symptoms as significant
hindrances to acceptance in school, athletics, and social
activities; and 20% had potential symptoms of reactive
depression, including loss of appetite, withdrawal from
social interaction, crying episodes, loss of interest in
activities, or loss of self-esteem.65 Another study used
semistructured interviews of approximately 90 minutes’
duration with nine adolescents and young adults (mean
age 20.8 years) diagnosed with narcolepsy.82 Study par-
ticipants described such negative experiences as teachers
throwing things at them to wake them up; falling at a
dance due to cataplexy; lacking adequate energy to per-
form at a full-time job; inability to drive and falling
asleep on public transport; and being teased by other
children (e.g., being made to laugh so he or she would
fall).82 A supplementary figure illustrates the self-
expressed thoughts, feelings, and experiences of an eight
-year-old girl with narcolepsy who is a patient of one of
the authors (JAO).
BOI: Impact on academic performance and cognition
A summary of the methods and results of published
studies of the impact of narcolepsy on school perfor-
mance, QOL, and other domains of BOI for children is
presented in Supplemental Table 1.
Although few studies have evaluated the impact of
narcolepsy on intellectual functioning and learning with
use of formal neuropsychologic assessment measures,
multiple reviews and observational studies have noted
that narcolepsy is associated with impaired school per-
formance, which may be further exacerbated by the
sequelae of misdiagnosis and delayed diagnosis for these
students (Table 3).12,27,62,65,67 Academic performance
appears to deteriorate over time as schoolwork becomes
more complex and challenging67; as success in school
(and life) is also associated with success in interpersonal
FIGURE 3. Full-scale, verbal, and performance intelligence quotient scores (Wechsler Intelligence Scale for Children-III-UK) for each partici-
pant in a trial of 12 patients with narcolepsy aged 7 to 16 years (median age 10 years). Reproduced with permission from Taylor & Francis
Ltd (www.tandfonline.com): Dorris et al.29  2008.
FIGURE 4. Academic performance and health-related quality of life
(HR-QOL) scores from a study in 117 children with narcolepsy (95
[81%] with NT1, 22 [19%] with NT2; mean age 11.6 [§3.1] years)
versus 69 healthy control subjects. Age appropriate or modified ver-
sions of the Vecu et Sante Perçu par l'Enfant or de l'Adolescent were
used to measure HR-QOL. Adapted from Inocente et al.31
28 G. Plazzi et al. / Pediatric Neurology 85 (2018) 2132relationships, the fact that narcolepsy is associated with
psychosocial problems is equally concerning.67
In contrast, the few studies that applied formal neurocogni-
tive assessment measures have consistently reported intact
cognitive function, with mean full-scale intelligence quotient
(IQ) within the average range, despite academic struggles
(Supplemental Table 1).27,29,30 One study that evaluated 12
children referred to a narcolepsy clinic found that while no dis-
tinct cognitive impairments or domain-specific weaknesses
were observed, significant differences were found for Verbal
versus Performance scores in five (42%) patients, as compared
with 24% of normal children, suggesting an uneven cognitive
profile for some patients (Supplemental Table 1 and Fig 3).29
Another study of 13 children with NT1 also found that
while all patients had normal full-scale IQ (mean and/or
median not reported), there were significant disparities
in Verbal versus Performance IQ (Supplemental Table 1).30
In this sample, seven of 13 patients (53.8%) reported a
history of academic failure. Other studies have evaluated
academic performance in the context of overall QOL, and
reported similar, consistent evidence of impaired func-
tion at school among children and adolescents with nar-
colepsy versus healthy control subjects (Supplemental
Table 1).26,28,31,32 For example, a study of 117 patients
with narcolepsy (95 with NT1, 22 with NT2), which eval-
uated academic performance on the basis of interviews
with children and their parents, reported higher rates of
school difficulties among the narcolepsy patients versus
69 control subjects31 (Fig 4).
BOI: Impact on QOL and behavior
No instruments to measure health-related QOL specifi-
cally in pediatric narcolepsy were available until 2017,
when the NARQoL-21 was developed and reported to
have promising psychometric qualities.94 Previous studies
of the BOI of pediatric narcolepsy have used general,
validated measures of pediatric QOL and health-related
QOL as well as behavioral measures (Supplemental
Table 1).95-99
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review that evaluated QOL in pediatric narcolepsy using
measurement scales for children, results have been
mixed (Supplemental Table 1). The study in 117 patients
with narcolepsy (described above in the section on aca-
demic performance), which evaluated the QOL with the
Vecu et Sante Perçue de l'Adolescent, reported signifi-
cantly lower scores overall and in most subdomains of
health-related QOL (Fig 4).31 Similarly, a study of 33
patients with central hypersomnia, including 18 with
narcolepsy (seven with NT1 and 11 with NT2), found that
the participants with central hypersomnia had signifi-
cantly lower scores for overall QOL and all subdomains,
except for Emotional Functioning, versus control subjects,
as determined via the Pediatric Quality of Life Inventory
4.0 Generic Core Scales.32 A study of 42 patients with
NT1 and 18 with EDS of uncertain etiology also reported
that both patients with NT1 and EDS had significantly
worse scores than control subjects (n = 23) on the Child
Health Questionnaire for Mental health; however, no dif-
ferences were seen for Physical and Global health
domains.28 The fourth study also found that patients
with NT1 (n = 29) and control subjects (n = 39) had simi-
lar scores in three of four Pediatric Quality of Life Inven-
tory 4.0 Generic Core Scale domains (physical, emotional,
and social), although NT1 patients had significantly lower
scores for School Functioning (P < 0.001) and Psychoso-
cial Health Summary (P = 0.01).26
Findings for behavioral measures, reported in four studies,
have been more consistent (Supplemental Table 1). Of two
small studies that conducted behavioral evaluation without
control groups, one (n = 12) reported clinically significant
problems in each of the various domains of the Achenbach
Child Behavior Checklist (parent reported) for approximately
15% to 50% of patients,29 and the other found worse-than ref-
erence mean values for at least one domain of the Strengths
and Difficulties Questionnaire in eight of 13 (62%) patients.30
The study in 42 patients with NT1 and 18 with EDS of uncer-
tain etiology, also noted above, reported significantly worse
scores versus healthy control subjects and compared with ref-
erence mean values, for Total and subdomain scores (P 
0.01).28 The fourth study of this group also reported signifi-
cantly worse Achenbach Child Behavior Checklist Total and
specific domain values in patients with NT1 (n = 29) versus
control subjects (n = 39) (P  0.02).26
Among other results, one QOL study reported signifi-
cantly higher rates of depression in patients with NT1
versus control subjects (P < 0.01),28 although another
study found that the rate of depression was not signifi-
cantly higher in patients with narcolepsy (NT1 and NT2)
versus control subjects (25% versus 15.6%).31 The study of
33 patients with central hypersomnia also found that
measures of wellness (higher rates of injury, less overall
physical activity, and time spent on homework) were sig-
nificantly worse (P < 0.05) in the patients versus control
subjects.32
Future directions
The emerging research on BOI of pediatric narcolepsy in
children supports long-time clinical observations thatnarcolepsy is a particularly difficult condition for children and
families to cope with, especially given the frequent long lag
time to diagnosis and treatment, the lifelong nature of the dis-
order, uncertainty regarding natural history and prognosis and
limited treatment options in pediatric narcolepsy. The low
prevalence of narcolepsy in children and general lack of public
awareness of this disorder further exacerbates the sense of iso-
lation that many of these children and families may feel, and
when coupled with health care providers’ often limited knowl-
edge regarding the disorder as well societal perceptions that
equate “sleepiness” with “laziness” and increased need for
sleep with physical or moral “weakness,” further delays diag-
nosis. Thus, the development of tailored educational programs
and screening tools, targeting medical providers and the gen-
eral public, as well as teachers, school nurses, school counse-
lors and other adults involved in promoting child health and
functioning, would be critical to improving QOL and reducing
BOI in pediatric narcolepsy. Policies at the district, county,
statewide, and national levels may include school-based indi-
vidual education plans (“IEPs” in the US and Europe in various
languages) which ensure that students with narcolepsy, as
with other medical disabilities, receive the appropriate envi-
ronmental and academic accommodations. Standardized
requirements for driving licensure in adolescents with narco-
lepsy, including selection of measurement tools to assess
sleepiness and “fitness to drive” requirements for compliance
with prescribed medications, and alternative strategies such as
napping, are needed.
There are also many clinical research questions
regarding BOI in children with narcolepsy that need to
be answered. For example, although cognitive function
seems largely intact in children with narcolepsy, some
inconsistencies across cognitive domains have been iden-
tified and should be further investigated. Little is known
about how the onset of NT1 in very young children may
impact neurodevelopment or alter the trajectory of
behavior, mood, and cognitive regulation. The impact of
pharmacologic treatment of both EDS and cataplexy on
cognitive domains such as executive functions, behavioral
domains such as impulse control, and emotional domains
including anxiety and depressive symptoms and self-
esteem, should be explored. Moreover, little is known
about the impact of nonpharmacologic interventions
such as scheduled naps, sleep extension, increased physi-
cal activity, changes in nutrition, strategic caffeine use, or
yoga and mindfulness in children and adolescents with
narcolepsy, or about the specific factors which influence
compliance with medication regimens. The role of sub-
stance abuse, particularly self-medication of sleepiness,
among adolescents and its potential to complicate narco-
lepsy detection and diagnosis is a neglected area of
research that should be further investigated.
Conclusions
Narcolepsy may impose a substantial BOI on children,
particularly when it remains undiagnosed and untreated
for many years. Tailored education campaigns are needed
to increase narcolepsy disease recognition and to
improve time to diagnosis; heighten attention to symp-
toms associated with narcolepsy, which may include
30 G. Plazzi et al. / Pediatric Neurology 85 (2018) 2132impaired school performance, social function, and
increased risk of psychiatric disorders; and to improve
implementation of screening procedures. Additional stud-
ies are also needed to evaluate more fully the extent of
BOI of narcolepsy in children and adolescents, correlates
of specific components of narcolepsy-associated BOI, the
potential risk of substance abuse among adolescents with
narcolepsy, and implications in adulthood for nonrecog-
nition and undermanagement of childhood narcolepsy.
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